Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review

CONCLUSION: To our best knowledge, this is the largest SSc cohort tested for NOR90 to date, confirming the NOR90 prevalence in SSc patients is around 3 %.PMID:38599922 | DOI:10.1016/j.ejim.2024.03.035

Source: European Journal of Internal Medicine - April 10, 2024 Category: Internal Medicine Authors: A Dima M C Vonk A Garaiman B E Kersten R Becvar M Tomcik A-M Hoffmann-Vold I Castellvi Jl Tandaipan Jaime M Brzosko M Milchert D Krasowska M Michalska-Jakubus P Airo M Matucci-Cerinic C Bruni M Iudici Jhw Distler A M Gheorghiu H Poormoghim F Motta M De Sa Source Type: research